biomedicina slovenica

re="Farm Vestn" : 201-300

  1. Herman D; Peternel P; Stegnar M; Breskvar K; Dolžan V
    The influence of CYP2C9 genotype, physiological factors and concomitant drug treatment on warfarin dose requirement
    2003 ►
  2. Bele M; Mesarič T; Planinšek O; Salobir M; Srčič S; Jamnik J
    Silica coatings on clarithromycin
    2003 ►
  3. Grandovec A; Perc S; Ocepek U
    Maillard reaction of lactose and 2-(2-aminoethoxy)-methyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid, 3-ethyl 5-methyl ester maleate, a primary amine
    2003 ►
  4. Zega A; Šuštarič A; Srčič S
    Quantitative analysis of mixtures of crystalline and amorphous felodipine by near-infrared spectroscopy
    2003 ►
  5. Perišič I; Ritlop G; Grandovec A
    Development of discriminatory dissolution tests for immediate release oral dosage form
    2003 ►
  6. Ritlop G; Makuc S; Černoša L; Vrečer F
    Designing and optimisation of dissolution methods: flow-through cell as a basis for development of dissolution tests for modified release delivery oral dosage forms
    2003 ►
  7. Roškar R; Kmetec V
    A comparison of BET and GAB approach for studying moisture sorption behavior of several excipients
    2003 ►
  8. Podlogar F; Bešter-Rogač M; Gašperlin M
    Structural characterization of water - Tween 40/Imwitor 308 - isopropyl myristate microemulsions by DSC and SAXS
    2003 ►
  9. Jurkovič P; Gašperlin M
    Influence of microemulsion type and thickening on ascorbyl palmitate dermal delivery
    2003 ►
  10. Dreu R; Širca J; Pintye-Hodi K; Srčič S
    Tensile strength and disintegration time of pellets prepared by extrusion and spheronisation technology as function of different granulating liquids
    2003 ►
  11. Planinšek O; Pišek R; Vrečer F; Srčič S
    Layering of pellets with two model drugs
    2003 ►
  12. Svete Peter; Jaklič Miha T
    Does increase in tablet hardness always result in slower dissolution rate?
    2003 ►
  13. Mateović T; Bogataj M; Ratnik M; Mrhar A
    Dependance of microspheres solidification time on initial temperature in solvent evaporation process
    2003 ►
  14. Leskošek T; Vrečer F; Pišek R
    The study of influence of disintegrant amount and type on physico-technological properties of the pellets produced in a high shear mixer
    2003 ►
  15. Pišek R; Ritlop G; Krošelj V; Kramar A; Vrečer F
    The influence of matrix composition and hydrophilic coating on dissolution properties of model drug
    2003 ►
  16. Kotar-Jordan B; Grčman M; Ograjšek N; Vrečer F
    Solid state characterization of new pantoprazole sodium hydrate forms and its amorphous form
    2003 ►
  17. Zupančič V; Kotar-Jordan B; Grčman M; Ograjšek N; Vrečer F
    Characterization of two pantoprazole sodium hydrates
    2003 ►
  18. Zajc N; Obreza A; Srčič S
    Physical stability of nifedipine solid dispersions prepared by hot melt method - a DSC and MTDSC study
    2003 ►
  19. Tivadar A; Kočevar K; Muševič I; Kerč J; Srčič S
    Study of felodipine transformation from glassy to crystalline state
    2003 ►
  20. Tivadar A; Kočevar K; Muševič I; Srčič S
    Surface analysis of polymer films by atomic force microscopy
    2003 ►
  21. Bešter-Rogač M; Rus L; Srčič S
    Volumetric characterization of some dihydropyridine derivates
    2003 ►
  22. Vajs A; Smrkolj M; Sitar-Čurin A; Grčman M
    Study of polymorphism of 1-cyclopropyl-6-fluoro-1,4-dihydro-8-metoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid
    2003 ►
  23. Ferlan A; Punčuh-Kolar A
    Some aspects of reducing drug particle size
    2003 ►
  24. Preskar M; Punčuh-Kolar A; Planinšek O; Vrečer F
    Study of the influence of formulation and process variables onto dissolution kinetics of granules and tablets
    2003 ►
  25. Preskar M; Punčuh-Kolar A; Vrečer F
    Study of influence of particle size and powder surface area on the technological relevant properties of model drug KD-9102
    2003 ►
  26. Mlinarič-Raščan I
    Thiopurine methyltransferase pharmacogenetics
    2003 ►
  27. Jeras M; Maličev E; Radosavljevič D; Knežević M; Kregar-Velikonja N
    Selected biocompatible and biodegradable matrices as templated for in vitro preparation of implantable human living cartilage tissue substitutes
    2003 ►
  28. Planinšek O; Bele M; Kunaver M; Zadnik J; Srčič S
    Influence of particle formation route on lactose physicochemical properties
    2003 ►
  29. Baumgartner S; Slameršek V; Kristl J
    Controlled drug delivery of hydrophilic drugs from cellulose ether matrix tablets: the influence of the drug molecule size on its release mechanism and kinetics
    2003 ►
  30. Cegnar Mateja; Premzl Aleš; Zavašnik-Bergant Valentina; Kristl Julijana; Kos Janko
    Effect of polymer type on the activity of cystatin encapsulated in poly(lactide-co-glycolide) nanoparticles and their uptake in MCF-10A neoT cells
    2003 ►
  31. Fočo Alma; Kristl Julijana
    Formulation and evaluation of liposomes as carriers for sodium ascorbyl phosphate into the skin
    2003 ►
  32. Legen Igor; Kristl Albin
    Multidrug resistance associated protein 2 (MRP2) activity in the rat small intestine in vitro
    2003 ►
  33. Kerec M; Bogataj M; Veranič P; Mrhar A
    The role of calcium ions in the mechanism of chitosan enhanced drug permeability into the pig urinary bladder wall
    2003 ►
  34. Bohanec Simona
    Experimental design as a tool for preformulation studies
    2003 ►
  35. Pišek Robert
    Macroscopic physical properties of powders and granules
    2003 ►
  36. Planinšek Odon
    Surface characterization of solid materials
    2003 ►
  37. Vrečer F
    Polymorphism and pseudopolymorphism
    2003 ►
  38. Srčič S
    Spectroscopic methods in preformulation and formulation studies
    2003 ►
  39. Kristl A
    Solubility of drugs
    2003 ►
  40. Urleb Uroš
    Molecular design
    2003 ►
  41. Štrukelj Borut
    The imapct of modern biotechnology on the pharmaceutical, medical and environmental development
    2003 ►
  42. Kersnik Janko
    Varna uporaba zdravil: pomen sodelovanja zdravnika družinske medicine in farmacevta
    2003 ►
  43. Primožič Stanislav
    Preklop Rp-BRp je tudi preklop odgovornosti - čigave?
    2003 ►
  44. Milovanovič Meta
    Farmacevtska skrb za bolnike s kardiovaskularnimi boleznimi
    [Pharmaceutical care for patients with cardiovascular disease]
    2003 ►
  45. Mlinarič Aleš
    Učinkovine rastlinskega izvora v preventivi kardiovaskularnih bolezni
    [Substances of plant origin in the prevention of cardiovascular diseases]
    2003 ►
  46. Prelec-Lainščak Jolanda
    Vpliv prehrane na razvoj bolezni srca in ožilja
    [Influence of nutrition on the development of cardiovascular diseases]
    2003 ►
  47. Čakš Tomaž
    Pogledi zdravnika na preventivo bolezni srca in ožilja
    [Physician's view on the prevention of cardiovascular diseases]
    2003 ►
  48. Fuerst Jurij; Peklar Jure
    Farmakoepidemiološki vidik zdravljenja hiperlipidemij
    [Pharmacoepidemiology of treatment of hyperlipidemy]
    2003 ►
  49. Bogataj Marija
    Farmakokinetske in farmakodinamske interakcije statinov
    [Pharmacokinetic and pharmacodynamic interactions of statins]
    2003 ►
  50. Osredkar Joško
    Stopenjska laboratorijska diagnostika kardiovaskularnih bolezni
    [Stes in laboratory diagnostic of cardiovascular diseases]
    2003 ►
  51. Vrečer Mateja
    Uporaba statinov v primarni in sekundarni preventivi koronarne bolezni srca in možganske kapi
    [Use of statins in primary and secondary prevention of coronary heart disease and stroke]
    2003 ►
  52. Šabovič Mišo
    Ateroskleroza in kardiovaskularne bolezni: (pomen "aktivne" vloge vnetja v procesu ateroskleroze)
    [Atherosclerosis and cardiovascular diseases]
    2003 ►
  53. Moravec-Berger Daša; Pečar-Čad Silva
    Epidemiologija kardiovaskularnih bolezni
    [Epidemiology of cardiovascular diseases]
    2003 ►
  54. Frankič Darja
    Javnozdravstveni vidik preklopljenih zdravil
    [Public health aspect of switched drugs]
    2003 ►
  55. Cranz Hubertus
    The European OTC market
    2003 ►
  56. Mrhar Aleš
    Beseda gostujočega urednika
    2003 ►
  57. Keber Irena
    Smernice za zdravljenje dislipidemij
    [Guidelines for dyslipidemia treatment]
    2003 ►
  58. Lovišček Ljubica
    40 let Mariborskih lekarn
    2002 ►
  59. Kuhar Vesna; Mrhar Aleš
    Povzetek glavnih značilnosti zdravila in navodilo za uporabo zdravila
    [Summary of product characteristics and patient information leaflet]
    2002 ►
  60. Tivadar Andrijana; Kočevar Klemen; Muševič Igor; Srčič Stanko
    Mikroskopija na atomsko silo
    [Atomic force microscopy]
    2002 ►
  61. Cesar Jožko; Šegula Mojca; Sollner-Dolenc Marija
    Novejše antiagregatorne učinkovine: antagonisti fibrinogenskega GPIIb/IIIa receptorja
    [Novel antiagrregatory drugs: firbrinogen GPIIb/IIIa receptor antagonists]
    2002 ►
  62. Peternel Luka; Sollner-Dolenc Marija
    Novejši pristopi k zdravljenju astme
    [New approaches in asthma therapy]
    2002 ►
  63. Smolej Marjetka; Gašperlin Mirjana
    Nega kože pri bolnikih z rakom
    [Skin care for cancer patients]
    2002 ►
  64. Predin Štefan
    Dušanu Valenčiču, mag. farm. spec., v slovo: (1912-2001)
    2001 ►
  65. Tumova Lenka; Brancuzka Renata; Tuma Jiri
    The effects of salicylic acid on flavonoid production in Ononis arvensis tissue culture
    [Vpliv salicilne kisline na biosintezo flavonoidov v tkivnih kulturah njivskega gladeža (Ononis arvensis)]
    2001 ►
  66. Uran Apolonija; Krbavčič Aleš; Cvelbar Martina
    Vrečke za kri in krvne sestavine
    [Containers for blood and blood components]
    2001 ►
  67. Bitenc-Logar Darja; Černelč Peter
    Celični označevalci za opredelitev mieloičnih in limfatičnih novotvorb
    [Cell markers for determination myeloid and lymphoid neoplasms]
    2001 ►
  68. Anderluh Marko; Sollner-Dolenc Marija
    Antagonisti trombinskega receptorja
    [Thrombin receptor antagonists]
    2001 ►
  69. Špiclin Polona; Gašperlin Mirjana
    Vitamin C in koža
    [Vitamin C and the skin]
    2001 ►
  70. Videnšek-Podgorelec Ana
    Prenosljive spongiformne encefalopatije
    [Transmissible spongiform encephalopathies]
    2001 ►
  71. Zupančič Vinko; Kikelj Danijel
    Kiralne zdravilne učinkovine v farmacevtski industriji - razvoj in uporaba
    [Chiral drugs in pharmaceutal industry - development and application]
    2001 ►
  72. Peklar J; Tratar F; Mrhar A
    Stroškovna učinkovitost uvedbe Obrazca za naročilo antibiotika v Splošni bolnišnici Celje
    [Cost effectiveness analysis of implementation of drug formulary for antimicrobials in General hospital Celje]
    2001 ►
  73. Zupančič Vinko; Krbavčič Aleš
    Dietilftalat - analizna monografija
    [Diethyl phthalate - analytical monograph]
    2001 ►
  74. Slanc Petra
    Halucinogene rastline: nahajališče, kemizem in delovanje
    [The hallucinogenic plants: plant sources, chemistry and effects]
    2001 ►
  75. Planinšek Odon
    Nekatere metode za povečevanje topnosti in hitrosti raztapljanja v vodi težko topnih učinkovin - 1. del
    [Some methods for solubility and dissolution rate increase of in water insoluble drugs - part - 1]
    2001 ►
  76. Predin Štefan
    Mr. ph. Franc Minarik (1887 - 1972): zgodovinar farmacije, pedagog in zbiratelj
    1997 ►
  77. Abram Veronika; Simčič Marjan
    Fenolne spojine kot antioksidanti
    [Phenols as antioxidants]
    1997 ►
  78. Zadravec Darko; Kerč Janez; Kristl Julijana
    Metode za izboljšanje biološke uporabnosti peptidnih učinkovin v peroralnih farmacevtskih oblikah
    [Methods for the improvement of oral bioavailability of peptide drugs]
    1997 ►
  79. Breznik M; Pečar S
    Trombinski inhibitorji
    [Thrombin inhibitors]
    1997 ►
  80. Predin Štefan
    Umrl je Janez Kromar, mr. ph., spec.
    2002 ►
  81. Pukšič Milan
    Štefan Predin, mag. farm. - akademik pri Mednarodni akademiji za zgodovino v Haagu
    2002 ►
  82. Lukač-Bajalo Jana; Kramberger Marta
    Vizija o razvoju klinične biokemije na 40-letnih temeljih
    [Fiture prospects of clinical biochemistry: its further development on four decades of groundwork]
    2002 ►
  83. Prezelj Marija; Zorec-Karlovšek Majda
    Transferin z zmanjšano vsebnostjo oglikohidratov v diagnostiki škodljive rabe alkohola
    [Carbohydrate deficient transferrin in the diagnosis of harmful alcohol use]
    2002 ►
  84. Oblak Marko; Šolmajer Tomaž
    Matrične metaloproteinaze - nove tarče antitumornih učinkovin
    [Matrix metalloproteinases - novel targets of antitumor drugs]
    2002 ►
  85. Štrancar Katja; Rozman Tanja; Kozjek Franc
    Genetski polimorfizmi in optimizacija farmakoterapije
    [Genetic polymorphism and optimization of drug therapy]
    2002 ►
  86. Rozman Tanja; Štrancar Katja; Kozjek Franc
    Farmakogenomika in razvoj novih zdravil
    [Pharmacogenomics and drug development]
    2002 ►
  87. Gruden Kristina
    Tehnologija genskih mikromrež in njihova uporaba v farmaciji
    [DNA microarrays technology and its application in pharmacy]
    2002 ►
  88. Antolič Gorazd; Novak-Antolič Živa
    Zdravila v času dojenja
    [Drugs during berast-feeding]
    2002 ►
  89. Marc Gašper
    Farmakoterapija debelosti
    [Pharmacotherapy of obesity]
    2002 ►
  90. Čibej-Žagar Barbara
    Psihosocialni vidik motenj hranjenja
    [Psycho social aspect of eating disorders]
    2002 ►
  91. Sernec Karin
    Motnje hranjenja
    [Eating disorders]
    2002 ►
  92. Krnjak Ljuba; Trunk Primož; Geršak Borut; Osredkar Joško
    Biokemični in klinični pomen koncentracije proteina S100B pri bolnikih, operiranih na srcu
    [Biochemical and clinical significance of protein S100B concentration at patients undergoing coronary artery bypass grafting]
    2002 ►
  93. Lenart Katarina; Zaletel Jelka; Černe Darko; Osredkar Joško
    Uporaba sinistrinskega očistka za oceno ledvične funkcijske rezerve pri bolnikih s sladkorno boleznijo tipa 1
    [Use of sinistrin clearance for estimation of renal functional reserve in patients with diabetes mellitus type 1]
    2002 ►
  94. Vrbinc Miha; Kmetec Vojko
    Fizikalna stabilnost in kompatibilnost trdnih snovi v predformulacijskih študijah trdnih farmacevtskih oblik
    [Physical stability and compatibility of solid-state substances in preformulation studies of solid dosage forms]
    2002 ►
  95. Jerin Aleš
    Metode za določanje homocisteina
    [Methods for the determination of homocysteine]
    2002 ►
  96. Setnikar Nataša; Skitek Milan
    Določanje homocisteina v serumu pri hemodializnih bolnikih s končno odpovedjo ledvic
    [Determination of serum homocysteine in hemodialysis patients in end-stage renal disease]
    2002 ►
  97. Pajek Jernej; Kaplan-Pavlovčič Staša
    Homocistein v nefrologiji
    [Homocysteine in nephrology]
    2002 ►
  98. Skitek Milan
    Homocistein v luči novih spoznanj
    [Homocystein in the spotlight of the new conceptions]
    2002 ►
  99. Osredkar Joško
    Kardiovaskularna obolenja - laboratorijska diagnostika
    [Cardiovascular diseases - laboratory diagnostics]
    2002 ►
  100. Kobe Jasna Modrica
    Da ne bomo pozabili
    2002 ►

   1 101 201 301 401 501 601 701 801 901  

Nova poizvedba      Pripombe      Na vrh strani                        Inštitut za biostatistiko in medicinsko informatiko